Clonazepam
Clonazepam (Klonopin) is a benzodiazepine for seizures and panic; it causes dependence, is dangerous with opioids or alcohol, and withdrawal can include seizures.
Overview
Clonazepam, sold under the brand name Klonopin, is a benzodiazepine used to treat seizure disorders and panic disorder. It is longer-acting than some benzodiazepines and, like all of them, effective but carrying a real risk of tolerance and dependence with regular use. The familiar benzodiazepine hazards apply: it is dangerous in combination with opioids, alcohol, and other depressants, and abrupt discontinuation after regular use can be medically dangerous. Clonazepam is widely prescribed and also misused, and — as with other benzodiazepines — counterfeit pills sold illicitly are an increasing risk.
Source: MedlinePlus; DEA; PubChem CID 2802
Chemistry & mechanism of action
Clonazepam works like other benzodiazepines, enhancing the calming effect of the neurotransmitter GABA to slow central nervous system activity. This reduces the abnormal electrical activity behind seizures, dampens anxiety and panic, and produces sedation. The same suppression of CNS activity is why benzodiazepines endanger breathing in overdose and, especially, in combination with other depressants. With repeated use the brain adapts, producing tolerance and physical dependence; if the drug is then stopped abruptly, the nervous system rebounds into an over-excited state, which is what makes benzodiazepine withdrawal — including the risk of seizures — potentially dangerous.
Source: MedlinePlus; PubChem CID 2802
Effects
Clonazepam reduces anxiety and panic and suppresses seizures, while producing sedation, drowsiness, and muscle relaxation. Common effects include fatigue, poor coordination, dizziness, and impaired memory and concentration; some people experience paradoxical agitation or mood changes. It impairs driving and alertness. With repeated use, tolerance develops and dependence can form, sometimes within weeks. Stopping abruptly after regular use can cause rebound anxiety, insomnia, and a withdrawal syndrome that, in more serious cases, includes seizures — which is why it should never be stopped suddenly without medical guidance.
Source: MedlinePlus
Risks & harms
The two principal dangers mirror the benzodiazepine class. First, combination with other depressants: clonazepam taken with opioids, alcohol, or other sedatives compounds respiratory depression and is a frequent factor in fatal overdoses, with explicit regulatory warnings about benzodiazepine-and-opioid use. Second, withdrawal: after regular use, stopping suddenly can trigger seizures and other dangerous symptoms, so it must be tapered gradually under medical supervision rather than stopped abruptly and alone. The counterfeit market adds a third danger — pills sold illicitly as Klonopin may contain other benzodiazepines, unrelated drugs, or fentanyl in unpredictable amounts, so naloxone (over the counter in the U.S. since 2023) is worth having because these pills can cause an opioid overdose. If you suspect an opioid overdose from a counterfeit pill, give naloxone and call 911. For poisoning guidance call Poison Control at 1-800-222-1222; for substance-use support the SAMHSA National Helpline is 1-800-662-4357.
Source: MedlinePlus; DEA; FDA; SAMHSA
Legal status (US)
In the United States, clonazepam is a Schedule IV controlled substance under the Controlled Substances Act: it has an accepted medical use and a lower abuse potential than Schedule II or III drugs, but it still carries a recognized risk of abuse and dependence and is available only by prescription, with limits on refills. Possessing or selling it without a valid prescription is illegal, and counterfeit versions are illicit drugs regardless of labeling. Internationally, clonazepam is controlled under the United Nations Convention on Psychotropic Substances, with penalties varying by country. For country-by-country legal detail, see our legality pages.
Source: DEA; UN Convention on Psychotropic Substances (1971)
Drug laws and enforcement change and vary by country. This is not legal advice. Always confirm with the destination’s embassy or official drug authority before traveling, because penalties can be severe, including imprisonment.
Before you travel
Verify current rules with the destination country’s official drug authority and your own country’s embassy before traveling. Find the destination’s U.S. embassy & official country guidance →
Non-U.S. travelers: check your own government’s travel advisory and embassy.
If you’re detained or arrested abroad
Contact your own country’s embassy or consulate in the destination immediately, not the destination’s authorities. U.S. citizens: contact the nearest U.S. embassy/consulate and the U.S. State Department at +1-202-501-4444 (from abroad). If a U.S. citizen is arrested or detained abroad →
Images
Visual references coming soon.
If it’s too intense
If an experience becomes overwhelming, the goal is to stay safe and let it pass, most difficult experiences ease as the drug wears off.
- Get to a calm, safe space with someone you trust who is sober and can stay with you.
- Cool down if you’re overheating, move somewhere cool, remove extra layers, rest. Overheating is especially a risk with stimulants and MDMA.
- Sip water to thirst, but don’t over-hydrate. Drinking large amounts of plain water (especially after MDMA) can dangerously dilute your blood sodium (hyponatremia). Electrolytes help more than volume.
- Slow your breathing, long, slow exhales help settle a racing heart and anxiety.
- A sugary drink, fruit juice, or a snack can ease shakiness and the anxiety that comes with low blood sugar.
- Do not take more, and do not add another substance to manage it. Redosing or adding something else (including a sedative like a benzodiazepine) can make things worse, not better.
With depressants, the danger is over-sedation: if someone is very drowsy, hard to wake, or breathing slowly, treat it as an emergency.
Source: general harm-reduction guidance from SAMHSA, NIH/NIDA, and MedlinePlus, in our own words. Draft, not yet medically reviewed.
Forensic dossier
Draft · every field is source-cited or marked “Unknown, pending review”Identity
- PubChem CID
- 2802PubChem PUG-REST ↗ · retrieved 2026-06-18
- IUPAC name
- 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-onePubChem PUG-REST ↗ · retrieved 2026-06-18
- Molecular formula
- C15H10ClN3O3PubChem PUG-REST ↗ · retrieved 2026-06-18
- SMILES
- C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3ClPubChem PUG-REST ↗ · retrieved 2026-06-18
- InChIKey
- DGBIGWXXNGSACT-UHFFFAOYSA-NPubChem PUG-REST ↗ · retrieved 2026-06-18
- Synonyms / aliases
- klonopin, Klonopin, Rivotril, Chlonazepam, Iktorivil, Cloazepam, Clonazepamum, Ravotril, Rivatril, Clonazepam civ, AntelepsinPubChem PUG-REST + seed aliases ↗ · retrieved 2026-06-18
Composition
- Composition
- N/A — single compound (see Identity)
Physical / pill characteristics
- Dosage form
- HUMAN PRESCRIPTION DRUGopenFDA drug label ↗ · retrieved 2026-06-18
- Shape
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Color
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Imprint
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Score
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
Scheduling & legal status
- US schedule
- Unknown — pending review
- International
- Unknown, pending review
Effects, risks & interactions
- Effects
- Clonazepam is a long-acting benzodiazepine used both for panic disorder and, as an anticonvulsant, for certain seizure conditions. Like others in the class it enhances GABA to calm the nervous system, producing eased anxiety, sedation and muscle relaxation; its long duration gives a steadier, more sustained effect than the short-acting agents, which is part of why it is used for ongoing conditions.PubChem CID 2802 + DailyMed label ↗ · retrieved 2026-06-18
- Risks
- Clonazepam's long action means it lingers and can build up, bringing daytime drowsiness and impaired coordination. Its most serious danger, shared across the class, is the pairing with opioids or alcohol — co-depressants together can cause fatal respiratory depression. It produces tolerance and dependence, and because it is often taken long-term for seizures or panic, abrupt discontinuation is especially hazardous on two fronts: benzodiazepine withdrawal can itself provoke seizures and be life-threatening, and stopping an anticonvulsant suddenly can worsen an underlying seizure disorder. For both reasons it must be tapered slowly under medical care.PubChem CID 2802 + DailyMed label ↗ · retrieved 2026-06-18
- Interactions
- Clonazepam's labelling opens with the opioid warning: combining benzodiazepines and opioids risks overwhelming sedation, depressed breathing, coma and death, and such use is to be restricted to situations without an alternative. It cautions that alcohol and other CNS depressants add to the sedation, and notes interactions with drugs that affect how the liver metabolises it.DailyMed §7 / boxed warning ↗ · retrieved 2026-06-18
Pill catalog
Rx/OTC variants · openFDA + DailyMed (public domain) · draft, pending reviewThis drug comes in 136different versions. Make sure you’re looking at the right one, use the search above to find your exact pill by imprint, color, or shape.
Showing 24 of 136 variants
- Strength
- CLONAZEPAM 2 mg/1
- Imprint
- B5 UpArrowhead
- Color
- white
- Shape
- ROUND
- Form
- TABLET, ORALLY DISINTEGRATING
- Labeler
- Advagen Pharma Ltd
- Schedule
- CIV
- NDC
- 72888-137 ↗ · 2026-06-18
- Strength
- CLONAZEPAM 1 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Advanced Rx Pharmacy of Tennessee, LLC
- Schedule
- CIV
- NDC
- 80425-0357 ↗ · 2026-06-18
- Strength
- CLONAZEPAM .5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Advanced Rx of Tennessee, LLC
- Schedule
- CIV
- NDC
- 80425-0358 ↗ · 2026-06-18
- Strength
- CLONAZEPAM 1 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Cardinal Health 107, LLC
- Schedule
- CIV
- NDC
- 55154-4319 ↗ · 2026-06-18
- Strength
- CLONAZEPAM 1 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Preferred Pharmaceuticals Inc.
- Schedule
- CIV
- NDC
- 68788-8473 ↗ · 2026-06-18
- Strength
- CLONAZEPAM .5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Cardinal Health 107, LLC
- Schedule
- CIV
- NDC
- 55154-4318 ↗ · 2026-06-18
- Strength
- CLONAZEPAM 2 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CIV
- NDC
- 71335-9747 ↗ · 2026-06-18
- Strength
- CLONAZEPAM .5 mg/1
- Imprint
- 1 2 KLONOPIN
- Color
- ORANGE
- Shape
- ROUND
- Form
- TABLET
- Labeler
- H2-Pharma, LLC
- Schedule
- CIV
- NDC
- 61269-605 ↗ · 2026-06-18
- Strength
- CLONAZEPAM 1 mg/1
- Imprint
- 1 KLONOPIN
- Color
- BLUE
- Shape
- ROUND
- Form
- TABLET
- Labeler
- H2-Pharma, LLC
- Schedule
- CIV
- NDC
- 61269-610 ↗ · 2026-06-18
- Strength
- CLONAZEPAM 2 mg/1
- Imprint
- 2 KLONOPIN
- Color
- WHITE
- Shape
- ROUND
- Form
- TABLET
- Labeler
- H2-Pharma, LLC
- Schedule
- CIV
- NDC
- 61269-620 ↗ · 2026-06-18
- Strength
- CLONAZEPAM .5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- REMEDYREPACK INC.
- Schedule
- CIV
- NDC
- 70518-3960 ↗ · 2026-06-18
- Strength
- CLONAZEPAM 2 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Aphena Pharma Solutions - Tennessee, LLC
- Schedule
- CIV
- NDC
- 71610-749 ↗ · 2026-06-18
- Strength
- CLONAZEPAM 1 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CIV
- NDC
- 63629-1204 ↗ · 2026-06-18
- Strength
- CLONAZEPAM .5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CIV
- NDC
- 63629-1201 ↗ · 2026-06-18
- Strength
- CLONAZEPAM .5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CIV
- NDC
- 63629-1202 ↗ · 2026-06-18
- Strength
- CLONAZEPAM .5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CIV
- NDC
- 63629-1203 ↗ · 2026-06-18
- Strength
- CLONAZEPAM 2 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Preferred Pharmaceuticals Inc.
- Schedule
- CIV
- NDC
- 68788-8499 ↗ · 2026-06-18
- Strength
- CLONAZEPAM 1 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CIV
- NDC
- 63629-1205 ↗ · 2026-06-18
- Strength
- CLONAZEPAM 1 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- REMEDYREPACK INC.
- Schedule
- CIV
- NDC
- 70518-2334 ↗ · 2026-06-18
- Strength
- CLONAZEPAM 2 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CIV
- NDC
- 63629-1206 ↗ · 2026-06-18
- Strength
- CLONAZEPAM .5 mg/1
- Imprint
- CE 192
- Color
- white
- Shape
- ROUND
- Form
- TABLET
- Labeler
- Chartwell RX, LLC
- Schedule
- CIV
- NDC
- 62135-769 ↗ · 2026-06-18
- Strength
- CLONAZEPAM 2 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CIV
- NDC
- 63629-1207 ↗ · 2026-06-18
- Strength
- CLONAZEPAM 1 mg/1
- Imprint
- CE 193
- Color
- white
- Shape
- ROUND
- Form
- TABLET
- Labeler
- Chartwell RX, LLC
- Schedule
- CIV
- NDC
- 62135-770 ↗ · 2026-06-18
- Strength
- CLONAZEPAM .5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Proficient Rx LP
- Schedule
- CIV
- NDC
- 71205-827 ↗ · 2026-06-18
Dosage
Pending medical reviewer
